Artificial intelligence can help drug study teams solve operational, scientific and ethical challenges. For example, AI can be used to flag real-time trends emerging in drug trials that might otherwise not be obvious until the end of a study when all the data is analyzed.
John Hammergren, who has served as the company's CEO for nearly 20 years, will retire next year, and COO Brian Tyler will take his place.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The world of pharmaceuticals needs to be more actively engaged in the digital health movement, which likely represents a significant opportunity for new levels of engagement and marketing that isn’t being realized, according to a survey from Accenture. “The pharma industry is in a period of rapid and deep change, adapting to a changing health […]
Spread the word: As of February 18th, biopharmaceutical/medical technology organizations and group purchasing organizations (GPOs) can now register and set up their accounts with the Open Payments/Sunshine online database. Biopharmaceutical/medical technology companies are required to register with the database. Registration and data submission will have two phases: Phase 1: This phase will run February 18th […]
In the run up to the commercialization of its migraine pain patch drug delivery system, NuPathe (NASDAQ: PATH), a specialty pharmaceutical company, has raised $28 million in a private stock sale. The U.S. Food and Drug Administration has set a PDUFA date for January 17 next year when it will decide whether or not to […]
Industry veterans from Ernst & Young, Johnson & Johnson (NYSE:JNJ) and Deloitte are planning to launch a healthcare growth equity company to provide turnaround services and to help new companies get off the ground. Scheduled to open next month, the firm will help underperforming companies improve sales. It will also serve as a launchpad for […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Ossianix, an early stage biopharmaceutical startup that utilizes shark antibodies as a model for drugs to treat central nervous system disorders, has received a strategic investment from Danish pharmaceutical company H Lundbeck. The investment amount was not disclosed, but Dr. Frank Walsh, cofounder and CEO of Ossianix, said it would be enough to fund the […]
CorMedix (NYSE:CRMD), a Bridgewater, New Jersey-based therapeutic product developer for the prevention and treatment of cardiorenal disease, has added a pharmaceutical veteran to its board of directors. Matt Duffy has worked for Pfizer (NYSE:PFE) in sales, marketing and product management, and was the first product manager for Viagra. He has led the marketing group at […]